Refine Search

Search Results -

Terms	Documents
L2	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L4

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, January 22, 2008 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB; PLUR=YES; OP=OR			
L4	L2	0	L4
DB=USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L3	L2	0	L3
DB=USPT; PLUR=YES; OP=OR			
L2	dalbavancin	11	L2
L1	dalbavancin	11	L1

END OF SEARCH HISTORY

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:58:34 ON 22 JAN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:58:50 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3
DICTIONARY FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s dalbavancin
L1 8 DALBAVANCIN

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.61	5.82

FILE 'CA' ENTERED AT 12:59:10 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 17 Jan 2008 (20080117/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1 and stabilizer
           103 L1
         87272 STABILIZER
L2           2 L1 AND STABILIZER

=> d l2 1-2
```

L2 ANSWER 1 OF 2 CA COPYRIGHT 2008 ACS on STN
AN 142:120514 CA
TI Dalbavancin compositions for treatment of bacterial infections
IN Stogniew, Martin
PA Vicuron Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 714,261.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005004050	A1	20050106	US 2004-834395	20040427
	US 7119061	B2	20061010		
	US 2004142883	A1	20040722	US 2003-714261	20031114
	US 6900175	B2	20050531		
	US 2004197415	A1	20041007	US 2004-828439	20040416
	US 7115564	B2	20061003		
	US 2004198715	A1	20041007	US 2004-828483	20040416
	US 2004220122	A1	20041104	US 2004-828379	20040416
	US 2004224908	A1	20041111	US 2004-829068	20040420
	US 2005004051	A1	20050106	US 2004-860723	20040602
	US 2005032721	A1	20050210	US 2004-942197	20040915
	US 2005130914	A1	20050616	US 2004-942604	20040915
	US 2006074014	A1	20060406	US 2005-116064	20050426
	AU 2005325261	A1	20060727	AU 2005-325261	20050426
	CA 2564112	A1	20060727	CA 2005-2564112	20050426
	WO 2006078277	A2	20060727	WO 2005-US14355	20050426
	WO 2006078277	A3	20061019		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1748786	A2	20070207	EP 2005-856652	20050426
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,				

HR, LV, MK, YU

	CN 1964736	A	20070516	CN 2005-80018563	20050426
	BR 2005010269	A	20071030	BR 2005-10269	20050426
	JP 2007534768	T	20071129	JP 2007-510906	20050426
	US 2005277581	A1	20051215	US 2005-157364	20050620
	NO 2006004287	A	20061024	NO 2006-4287	20060921
	IN 2006DN05604	A	20070831	IN 2006-DN5604	20060926
	KR 2007015179	A	20070201	KR 2006-722355	20061026
PRAI	US 2002-427654P	P	20021118		
	US 2003-485694P	P	20030708		
	US 2003-495048P	P	20030813		
	US 2003-496483P	P	20030819		
	US 2003-714261	A2	20031114		
	US 2004-828483	A1	20040416		
	US 2005-116064	A2	20050426		
	WO 2005-US14355	W	20050426		

RE.CNT 188 THERE ARE 188 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 2 CA COPYRIGHT 2008 ACS on STN
AN 141:1208 CA
TI Dalbavancin compositions for treatment of bacterial infections
IN Colombo, Luigi; Malabarba, Adriano; Stogniew, Martin
PA Vicuron Pharmaceuticals Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045637	A1	20040603	WO 2003-US36779	20031114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003298662	A1	20040615	AU 2003-298662	20031114
	US 2005004011	A1	20050106	US 2003-713924	20031114
	US 2005130909	A1	20050616	US 2003-714166	20031114
	CN 1711102	A	20051221	CN 2003-80103406	20031114
	US 2005032721	A1	20050210	US 2004-942197	20040915
	US 2005130914	A1	20050616	US 2004-942604	20040915
	US 2005090433	A1	20050428	US 2004-493558	20041122
PRAI	US 2002-427654P	P	20021118		
	US 2003-485694P	P	20030708		
	US 2003-495048P	P	20030813		
	US 2003-496483P	P	20030819		
	US 2003-714261	A1	20031114		
	WO 2003-US36779	W	20031114		
	US 2004-828483	A1	20040416		

=> d l2 1-2 an ab

L2 ANSWER 1 OF 2 CA COPYRIGHT 2008 ACS on STN
AN 142:120514 CA
AB The invention provides methods and compns. for treatment of bacterial

infections. A dosage form comprises a sterile, stable, particle-free dalbavancin powder and a stabilizer, i.e., mannitol and/or lactose, wherein the dosage form degrades by no more than about 2% at about 40° after about 3 mo. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-pos. bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the blood stream for at least one week, providing prolonged therapeutic action against a bacterial infection. For example, a single 1000 mg i.v. dose of dalbavancin was well-tolerated in healthy subjects. Following a single i.v. infusion of 1000 mg, plasma concns. of dalbavancin above 45 mg/L were maintained for at least 7 days, which is above concns. known to be bactericidal (4-32 mg/L). This supports the use of dalbavancin as a once-weekly regimen. The urinary elimination profile indicates that renal excretion is an important elimination pathway, with approx. 40% excreted in urine. Since the kidneys are not the exclusive elimination route, a dosing adjustment for dalbavancin may not be necessary in renally impaired patients. Also, dalbavancin given as an initial i.v. dose of 1000 mg followed 1 wk later by a second i.v. dose of 500 mg appears well tolerated and highly effective for the treatment of catheter-related blood stream infection caused by Gram-pos. pathogens, with superior response rates to vancomycin.

L2 ANSWER 2 OF 2 CA COPYRIGHT 2008 ACS on STN
AN 141:1208 CA
AB The invention provides methods and compns. for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for treatment of a bacterial infection, in particular a Gram-pos. bacterial infection of skin and soft tissue. Compns. comprise a mixture of dalbavancin multimer and monomer and a stabilizer, such as dextrose.

```
=> s l1
L3          103 L1

=> s l3 and ph
        1328917 PH
L4            3 L3 AND PH

=> d l4 1-3

L4   ANSWER 1 OF 3  CA  COPYRIGHT 2008 ACS on STN
AN   141:1208  CA
TI   Dalbavancin compositions for treatment of bacterial infections
IN   Colombo, Luigi; Malabarba, Adriano; Stogniew, Martin
PA   Vicuron Pharmaceuticals Inc., USA
SO   PCT Int. Appl., 107 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004045637        A1    20040603    WO 2003-US36779         20031114
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
```

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003298662	A1	20040615	AU 2003-298662	20031114
	US 2005004011	A1	20050106	US 2003-713924	20031114
	US 2005130909	A1	20050616	US 2003-714166	20031114
	CN 1711102	A	20051221	CN 2003-80103406	20031114
	US 2005032721	A1	20050210	US 2004-942197	20040915
	US 2005130914	A1	20050616	US 2004-942604	20040915
	US 2005090433	A1	20050428	US 2004-493558	20041122
PRAI	US 2002-427654P	P	20021118		
	US 2003-485694P	P	20030708		
	US 2003-495048P	P	20030813		
	US 2003-496483P	P	20030819		
	US 2003-714261	A1	20031114		
	WO 2003-US36779	W	20031114		
	US 2004-828483	A1	20040416		

L4 ANSWER 2 OF 3 CA COPYRIGHT 2008 ACS on STN
AN 141:1207 CA
TI Methods of administering dalbavancin for treatment of bacterial infections
IN Cavaleri, Marco; Henkel, Timothy; Jabes, Daniela; Malabarba, Adriano; Mosconi, Giorgio; Stogniew, Martin; White, Richard J.
PA Vicuron Pharmaceuticals Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004045636	A1	20040603	WO 2003-US336127	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506236	A1	20040603	CA 2003-2506236	20031114
AU 2003294262	A1	20040615	AU 2003-294262	20031114
AU 2003294262	B2	20070823		
US 2005004011	A1	20050106	US 2003-713924	20031114
US 2005130909	A1	20050616	US 2003-714166	20031114
EP 1565201	A1	20050824	EP 2003-789744	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1711102	A	20051221	CN 2003-80103406	20031114
JP 2006514092	T	20060427	JP 2004-570384	20031114
US 2005032721	A1	20050210	US 2004-942197	20040915
US 2005130914	A1	20050616	US 2004-942604	20040915
NO 2005002362	A	20050817	NO 2005-2362	20050512
IN 2005KN00873	A	20070126	IN 2005-KN873	20050512
MX 2005PA05338	A	20051214	MX 2005-PA5338	20050518
PRAI US 2002-427654P	P	20021118		
US 2003-485694P	P	20030708		
US 2003-495048P	P	20030813		
US 2003-496483P	P	20030819		
US 2003-714261	A1	20031114		
WO 2003-US36127	W	20031114		
US 2004-828483	A1	20040416		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CA COPYRIGHT 2008 ACS on STN
AN 139:281230 CA
TI Bioadhesive vaginal drug delivery system containing an acidic buffer
IN Kirschner, Mitchell I.; Levinson, R. Saul; Riley, Thomas C.; Hermelin, Marc S.
PA KV Pharmaceutical Company, USA
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003180366	A1	20030925	US 2002-101014	20020320
	US 6899890	B2	20050531		
	CA 2392473	A1	20030920	CA 2002-2392473	20020628
	CA 2392473	C	20070918		
	AU 2002300175	A1	20031009	AU 2002-300175	20020715
	MX 2002PA06943	A	20041213	MX 2002-PA6943	20020715
	BR 2002002767	A	20040525	BR 2002-2767	20020718
	IT 2002MI1660	A1	20040126	IT 2002-MI1660	20020726
	CN 1444926	A	20031001	CN 2002-127087	20020729
	CN 101045034	A	20071003	CN 2007-10104800	20020729
	JP 2003286193	A	20031007	JP 2002-266381	20020912
	HU 2002003102	A2	20040528	HU 2002-3102	20020918
	PT 102854	A	20030930	PT 2002-102854	20021015
	PT 102854	B	20040227		
	FR 2837389	A1	20030926	FR 2002-14858	20021127
	WO 2003079981	A2	20031002	WO 2003-US8266	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003218233	A1	20031008	AU 2003-218233	20030319
	ZA 2004007535	A	20060628	ZA 2004-7535	20040917
PRAI	US 2002-101014	A	20020320		
	CN 2002-127087	A3	20020729		
	WO 2003-US8266	W	20030319		

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 1-3 an ab

L3 ANSWER 1 OF 103 CA COPYRIGHT 2008 ACS on STN
AN 148:102 CA
AB A review. Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin-resistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Addnl., a number of new anti-MRSA compds. are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clin. issues surrounding

the newly marketed and investigational agents with activity against MRSA.

L3 ANSWER 2 OF 103 CA COPYRIGHT 2008 ACS on STN
AN 147:462234 CA
AB The invention discloses methods using antimicrobial compds. for preventing or reducing the risk of infection due to surgical or invasive medical procedures.

L3 ANSWER 3 OF 103 CA COPYRIGHT 2008 ACS on STN
AN 147:439375 CA
AB A review. Dalbavancin is a new lipoglycopeptide antibiotic in late-stage clin. development as a once-weekly treatment for serious infections including skin and skin structure infections. Its in vitro potency is greater than that of vancomycin, with a MIC90 of 0.06 mg/l for Staphylococcus aureus and coagulase-neg. staphylococci (irresp. of oxacillin susceptibility), 0.06-0.12 mg/l for vancomycin-susceptible Enterococcus spp. and 0.003 mg/l or less for Streptococcus pneumoniae or β-hemolytic streptococci. Dalbavancin has dual routes of elimination. The results of Phase II/III studies show clin. efficiency in complicated skin and skin structure infection. During clin. trials, dalbavancin was as effective as linezolid or vancomycin in the treatment of patients with complicated skin and skin structure infection, including those with methicillin-resistant S. aureus. An addnl. Phase II study demonstrated efficacy in catheter-related bacteremia. Other preliminary in vitro and in vivo data have identified putative interest of dalbavancin in endocarditis, osteitis, diabetic foot, respiratory tract or joint infection.